ESSENTIAL THROMBOCYTOSIS
DOI:
https://doi.org/10.29303/jku.v11i3.738Keywords:
neoplasma, mieloproliferatif, trombositosis esensialAbstract
Myeloid neoplasm occurs when myeloid clonal cells proliferate excessively. One of the classifications of the disease is essential thrombocytosis. Essential thrombocytosis (TE) is a myeloproliferative disease characterized by excessive megakaryocyte proliferation which causes the number of platelets in the blood to exceed normal limits. TE can be caused by mutations in several genes, namely the genes JAK2, CALR or MPL. The diagnosis of TE is based on the results of the patient history, physical examination and other examinations, including laboratory tests. ET disease can be treated with several therapies including myelosuppression, antiplatelet, platelet-pheresis/thrombocytopheresis, and JAK inhibitors. Based on the course of the disease, ET is usually stable for 10-20 years or more. After years this disease can transform into myelofibrosis or other dangerous diseases if not treated properly.
References
2. Hoffbrand AV, Moss PA. Kapita Selekta HEMATOLOGI Edidi 7. In: Hartono H, Lestari WA, Alihbahasa. Suyono J, et al. editor. New York: ChurChill Living Stone, 2017.
3. Tefferi A et al. Essential thrombocythemia treatment algorithm 2018. Blood Cancer Journal. 2018. 8:2.
4. Harrison C, Okoli S. Emerging Treatments for Essential Thrombocythemia. Journal of Blood Medicine. 2011;2:151-159.
5. Meier B, Burton JH. Myeloproliferative Disorders. Hematol Oncol Clin North Am. 2017 Dec;31(6):1029-1044. [PubMed]
6. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014 Mar;55(3):595-600. [PubMed]
7. Gohari P, Ashrobi D. Essential Thrombocytosis (Essensial Thrombocythemia, ET). [Online]. 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539709/
8. Rodgers GM, Means RT. Thrombocytosis and Essential Thrombocythemia. In:Greer JP, Arber DA, Glader B, et al. Wintrobe’s Clinical Hematology13thed. Lippincott Williams & Wilkins. New York. 2013: 2593-2602.
9. Harrison C, Okoli S. Emerging Treatments for Essential Thrombocythemia. Journal of Blood Medicine. 2011;2:151-159.
10. Setiati S., Alwi I., Sudoyo AW., Simadibrata M., Setiyohadi B., Syam AF. Buku Ajar Ilmu Penyakit Dalam Jilid II. Edisi VI. Jakarta: Interna Publishing; 2014. 420-6
11. Buku Ajar Penyakit Dalam Edisi VI. Pusat Penerbit Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia, Jakarta.
12. National Heart, Lung, and Blood Institute. Thrombocythemia and Thrombocytosis. [Online]. 2017. Available from : https://www.nhlbi.nih.gov/health-topics/thrombocythemia-and-thrombocytosis.
13. Ashorob D, Pouyan G. Essential Thrombocytosis (Essential Thrombocythemia, ET). New York: StatPearls Publishing LCC. 2019 Mei 2. 1.
